Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02321774 · ClinicalTrials.gov registry record
Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment
A clinical trial, sponsored by Scripps Translational Science Institute.
- Completed
- Registry status
- 53
- Enrollment target
NCT02321774: Completed study, sponsored by Scripps Translational Science Institute.
NCT02321774 is a clinical trial that has completed, run by Scripps Translational Science Institute. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02321774 has completed, sponsored by Scripps Translational Science Institute.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
Monitor stress response in a virtual reality environment using a wearable sensor to analyze and track heart rate variability (HRV).
Primary Outcome
Collect continuous physiological data in real-time from participants undergoing a set of standardized stress exposure experiences.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-05 |
What the finished NCT02321774 record still lists
NCT02321774 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02321774 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02321774 about?
NCT02321774 is a clinical study titled "Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment". Monitor stress response in a virtual reality environment using a wearable sensor to analyze and track heart rate variability (HRV).
What is the current status of trial NCT02321774?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2014-11. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT02321774?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia